We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bristol Myers Squibb Teases Positive Phase 3 Data for Opdivo in NSCLC
Bristol Myers Squibb Teases Positive Phase 3 Data for Opdivo in NSCLC
Bristol Myers Squibb (BMS) unveiled positive interim results from its phase 3 CheckMate trial, showing that Opdivo (nivolumab) plus chemotherapy significantly improved event-free survival in patients with resectable IB-IIIA nonsmall-cell lung cancer (NSCLC).